Gilead’s revenues ‘flat’ for Q3 and ‘relatively unexciting’ excluding remdesivir sales

Gilead reported “flat” revenue for the third quarter compared to last year, with the company bringing in $7.1 billion largely thanks to increased sales of its oncology and HIV drugs but offset by lower Veklury (remdesivir) and chronic hepatitis C virus sales.

Oncology sales increased 33%…
Click here to view original post